EarningsPuma reported 2Q24 revenue and non-GAAP EPS of $47.1M and ($0.05), respectively, compared to estimates of $41.4M and ($0.14), respectively.
Legal/PatentPatent infringement win could reap financial benefits for Puma as the jury verdict found the patents to be infringed by AstraZeneca and not invalid, awarding the plaintiffs $107.5M in damages.
Product PerformanceNCCN guidelines include Nerlynx combinations as category 2B potential targeted therapies for patients with ER+/HER2- or ER-/HER2-metastatic (stage IV) breast cancer.